Array Biopharma Inc (ARRY)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3200 WALNUT STREET BOULDER, CO 80301

Operates as a biopharmaceutical company that focuses on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Its proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease.

Data based on most recent fiscal year report
Market Cap3.032 Billion Shares Outstanding197.03 Million Avg Volume6.003 Million
1-Yr BETA vs S&P TR1.399 Current Ratio3.88 Quick Ratio3.88
View SEC Filings from ARRY instead.
Q1 2018 All Institutions Hedge Funds 1
To trade ARRY now:
Filers who had this stock in their top 10: 7 5 (0.47%)
13F Filers holding this stock: 233 56 (5.29%)
Aggregate 13F shares on 03/31/2018: 195.015 Million 55.233 Million
Aggregate 13F shares on 12/31/2017: 200.279 Million 66.497 Million
Percent change: -2.63% -16.94%
Funds creating new positions: 65 20
Funds Adding to an existing position: 83 14
Funds closing out their position: 21 5
Funds reducing their position: 62 17
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ARRY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to

Exclude:

Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

373.7 Thousand total shares from 7 transactions

Exercise Derivative Conversion (M)

451 Thousand total shares from 11 transactions

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Acquired or Disposed Shares Owned Following Transaction Direct/Indirect Ownership

LEFKOFF KYLE - Director

2018-07-06 M 25,000 d 0 direct

LEFKOFF KYLE - Director

2018-07-06 M 25,000 a 67,720 direct

LEFKOFF KYLE - Director

2018-07-06 M 25,000 d 0 direct

LEFKOFF KYLE - Director

2018-07-06 M 25,000 a 42,720 direct

LEFKOFF KYLE - Director

2018-07-06 S 50,000 d 17,720 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-27 M 17,440 d 0 direct

SQUARER RON CEO

2018-06-27 S 140,625 d 211,575 direct

ROBBINS ANDREW R COO

2018-06-27 M 32,068 d 0 direct

SACCOMANO NICHOLAS A CSO

2018-06-27 F 5,038 d 61,693 direct

SQUARER RON CEO

2018-06-27 M 140,625 d 421,875 direct

SQUARER RON CEO

2018-06-27 F 34,253 d 255,203 direct

ROBBINS ANDREW R COO

2018-06-27 M 32,068 a 191,535 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-27 F 7,753 d 219,773 direct

SQUARER RON CEO

2018-06-27 M 140,625 a 352,200 direct

ROBBINS ANDREW R COO

2018-06-27 S 17,964 d 159,467 direct

SACCOMANO NICHOLAS A CSO

2018-06-27 M 11,453 a 66,731 direct

SQUARER RON CEO

2018-06-27 M 77,881 d 0 direct

SQUARER RON CEO

2018-06-27 M 77,881 a 289,456 direct

SACCOMANO NICHOLAS A CSO

2018-06-27 M 11,453 d 0 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-27 M 17,440 a 227,526 direct

SQUARER RON CEO

2018-06-27 S 43,628 d 211,575 direct

ROBBINS ANDREW R COO

2018-06-27 F 14,104 d 177,431 direct

VAN LUNSEN GIL J

2018-06-20 M 14,000 a 40,797 direct

VAN LUNSEN GIL J

2018-06-20 M 14,000 d 11,000 direct

VAN LUNSEN GIL J

2018-06-20 M 7,500 a 26,797 direct

VAN LUNSEN GIL J

2018-06-20 S 21,500 d 19,297 direct

VAN LUNSEN GIL J

2018-06-20 M 7,500 d 0 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-19 S 77,576 d 210,086 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-19 M 77,576 a 287,662 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-19 M 77,576 d 279,259 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-13 M 22,424 a 232,510 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-13 M 22,424 d 356,835 direct

SANDOR VICTOR CHIEF MEDICAL OFFICER

2018-06-13 S 22,424 d 210,086 direct
Click here to report any possible errors with this stock listing.

Elevate your investments